Intrexon | XON - Cash And Equivalent


Intrexon reported $9.34M in Cash and Equivalent for its fiscal quarter ending in June of 2024.





Cash And Equivalent Change Date
Agenus USD 18.74M 16.26M Jun/2026
Alaunos Therapeutics USD 124K 230K Jun/2026
Amgen USD 13.19B 799M Sep/2026
Anika Therapeutics USD 38.41M 2.61M Jun/2026
Arrowhead Research USD 19.68M 127.85M Jun/2026
AstraZeneca USD 4.89B 2.67B Jun/2026
Bristol-Myers Squibb USD 9.57B 852M Sep/2026
Gilead Sciences USD 3.18B 4.45B Jun/2026
GlaxoSmithKline GBP 3.1B 337M Jun/2026
Heron Therapeutics USD 20.72M 5.4M Jun/2026
Incyte USD 3.85B 127.8M Sep/2026
Intrexon USD 9.34M 1.77M Jun/2024
Karyopharm Therapeutics USD 90.85M 30.31M Mar/2026
Ligand Pharmaceuticals USD 55.96M 950.74M Sep/2026
MacroGenics USD 113.91M 47.39M Jun/2026
MannKind USD 41.28M 11.65M Sep/2026
Merck USD 9.55B 2.7B Sep/2026
Novartis USD 8.87B 1.25B Sep/2026
Rigel Pharmaceuticals USD 48.53M 4.87M Sep/2025
Roche Holding CHF 7.55B 579M Jun/2025
Sangamo BioSciences USD 38.34M 13.16M Jun/2025
Thermo Fisher Scientific USD 5.46B 1.4B Sep/2026
Veracyte USD 199.83M 99.69M Sep/2026
Xencor USD 59.62M 14.96M Sep/2026